Deutsche Bank’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-114,846
| Closed | -$305K | – | 3766 |
|
|
2024
Q1 | $305K | Hold |
114,846
| – | – | ﹤0.01% | 2597 |
|
|
2023
Q4 | $272K | Hold |
114,846
| – | – | ﹤0.01% | 2704 |
|
|
2023
Q3 | $161K | Hold |
114,846
| – | – | ﹤0.01% | 2920 |
|
|
2023
Q2 | $348K | Sell |
114,846
-18,034
| -14% | -$69.5K | ﹤0.01% | 2558 |
|
|
2023
Q1 | $831K | Buy |
132,880
+1,930
| +1% | +$11.8K | ﹤0.01% | 2211 |
|
|
2022
Q4 | $799K | Buy |
130,950
+196
| +0.1% | +$1.6K | ﹤0.01% | 2183 |
|
|
2022
Q3 | $1.56M | Sell |
130,754
-1,951
| -1% | -$25.5K | ﹤0.01% | 1726 |
|
|
2022
Q2 | $1.67M | Buy |
132,705
+667
| +0.5% | +$6.21K | ﹤0.01% | 1864 |
|
|
2022
Q1 | $1.49M | Sell |
132,038
-1,658
| -1% | -$18.3K | ﹤0.01% | 2080 |
|
|
2021
Q4 | $2.37M | Buy |
133,696
+830
| +0.6% | +$17.5K | ﹤0.01% | 1890 |
|
|
2021
Q3 | $3.06M | Buy |
132,866
+6,555
| +5% | +$143K | ﹤0.01% | 1793 |
|
|
2021
Q2 | $2.94M | Buy |
126,311
+99,184
| +366% | +$2.52M | ﹤0.01% | 1890 |
|
|
2021
Q1 | $845K | Buy |
+27,127
| New | +$945K | ﹤0.01% | 2768 |
|
Deutsche Bank's KNTE Position: Q2 2024 in Review
Deutsche Bank sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 114,846 shares — an estimated $305K sold.
Deutsche Bank first reported a position in KNTE in Q1 2021 and held it in 13 quarters. The position peaked at $3.06M in Q3 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Deutsche Bank reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Deutsche Bank sold 114,846 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $305K.
- Deutsche Bank first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- Deutsche Bank's Kinnate Biopharma Inc. Common Stock position peaked at $3.06M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Deutsche Bank's 13F filing for Q2 2024, filed 14 Aug 2024.